Online inquiry

IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15522MR)

This product GTTS-WQ15522MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TGM2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001323316.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7052
UniProt ID P21980
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15522MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9041MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ10114MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ15592MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ4103MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ7379MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ7598MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ13736MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ10204MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LDP-02
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW